Dr. Kian-Huat Lim, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Studies Pancreatic Cancer
Studies Stomach Cancer
24 reported clinical trials
51 drugs studied
About Kian-Huat Lim, M.D., Ph.D.
Education:
- Earned MD from National Taiwan University College of Medicine in 1999.
- Completed Molecular Cancer Biology Program at Duke University in 2006.
- Participated in the Physician-Scientist Training Program at Washington University School of Medicine in 2010.
Experience:
- Serves as an Associate Professor of Medicine at Washington University School of Medicine.
- Holds Board Certifications in Internal Medicine and Medical Oncology.
- Specializes in gastrointestinal oncology, focusing on colorectal, pancreatic, and hepatobiliary cancers.
- Research interests include exploring the link between inflammation and cancer progression and developing new treatments to improve chemotherapy and radiation responses.
- Affiliated with Barnes-Jewish Hospital and Barnes-Jewish West County Hospital.
Area of expertise
1Pancreatic Cancer
Stage IV
Stage III
Stage I
2Stomach Cancer
Stage IV
HER2 negative
Stage III
Affiliated Hospitals
Clinical Trials Kian-Huat Lim, M.D., Ph.D. is currently running
Chemotherapy + Radiotherapy
for Esophageal and Gastric Cancer
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Recruiting2 awards Phase 320 criteria
Defactinib + Radiotherapy
for Pancreatic Cancer
Patients with advanced pancreas adenocarcinoma will be randomized on a 6:1 basis to receive standard of care chemotherapy followed by adaptive stereotactic body radiotherapy (SBRT) with concurrent and adjuvant FAK inhibitor defactinib (experimental arm) or standard of care chemotherapy followed by SBRT (control arm). Patients enrolled to the experimental arm will be assessed for clinical outcomes such as progression free survival (PFS), local control, distant control, and toxicity. The first 6 patients randomized to the experimental arm will be considered the safety lead-in and will be assessed for dose-limiting toxicities (DLTs). The 6 patients randomized to the control arm will be evaluated for correlatives but will not be included in the analysis for primary and secondary endpoints.
Recruiting1 award Phase 219 criteria
More about Kian-Huat Lim, M.D., Ph.D.
Clinical Trial Related6 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 12 Active Clinical TrialsTreatments Kian-Huat Lim, M.D., Ph.D. has experience with
- Gemcitabine
- Nab-paclitaxel
- Nivolumab
- Oxaliplatin
- Leucovorin
- Defactinib
Breakdown of trials Kian-Huat Lim, M.D., Ph.D. has run
Pancreatic Cancer
Stomach Cancer
Uterine Tumors
Esophageal Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Kian-Huat Lim, M.D., Ph.D. specialize in?
Kian-Huat Lim, M.D., Ph.D. focuses on Pancreatic Cancer and Stomach Cancer. In particular, much of their work with Pancreatic Cancer has involved Stage IV patients, or patients who are Stage III.
Is Kian-Huat Lim, M.D., Ph.D. currently recruiting for clinical trials?
Yes, Kian-Huat Lim, M.D., Ph.D. is currently recruiting for 11 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Kian-Huat Lim, M.D., Ph.D. has studied deeply?
Yes, Kian-Huat Lim, M.D., Ph.D. has studied treatments such as Gemcitabine, Nab-paclitaxel, Nivolumab.
What is the best way to schedule an appointment with Kian-Huat Lim, M.D., Ph.D.?
Apply for one of the trials that Kian-Huat Lim, M.D., Ph.D. is conducting.
What is the office address of Kian-Huat Lim, M.D., Ph.D.?
The office of Kian-Huat Lim, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.